Business
Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales
LONDON, Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention,
About this update from Virax Biolabs Group Limited
[{"type":"text","content":"LONDON, Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs (\"Virax\" or the \"Company\") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales. \n\n \n \n \n \n \n \n\n \n\"We are thrilled to welcome Richard to our team,\" said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs. \"Richard brings almost 25 years of experience in successfully commercializing novel and disruptive technological products in the research, routine molecular diagnostic, and point-of-care testing markets globally. He is well suited to spearhead Virax's commercial capabilities.\" \nAs the Vice President of In Vitro Diagnostic Sales, Mr. Pallin will lead Virax's commercial team and lead the execution of the Company's go-to-market strategy. Prior to joining Virax, Mr. Pallin was the Vice President of Global Commercial Operations of Omixon, Inc., a global transplantation diagnostic company dedicated to transitioning the human leukocyte antigen community to Next Generation Sequencing (NGS) technologies. Prior to that, Mr. Pallin was the Director of Commercial Operations for Singulex, Inc., the developer and leading provider of single molecule counting technology for clinical diagnostics and scientific discovery. Mr. Pallin also previously held senior commercial roles at Genmark Diagnostics UK, Vela Diagnostics GmbH, Luminex B.V., Affymetrix, Inc. and Roche Diagnostics.\n\"Virax is building an exciting company developing and marketing innovative diagnostics in areas of significant need, I am excited to be in a position to accelerate the Company's sales and marketing activities and build a world class commercial organization. This is a key moment in the company's development and I look forward to doing my part to build on the full promise of the Company's exciting portfolio\" commented Mr. Richard Pallin.\nAbout Virax Biolabs Group Limited\nFounded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.\nIn addition to distributing an array of viral test kits in unique geographies, Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intenti...